Abstract
Purpose
The purpose of the study is to review our experience with concurrent chemoradiotherapy (CCRT) for patients with advanced resectable squamous cell carcinoma (SCC) of the hypopharynx and to evaluate the factors affecting survival and larynx preservation.
Study design
Retrospective study.
Methods and materials
The records of 102 patients with Stage III or IV resectable SCC of the hypopharynx treated with CCRT between January 1998 and August 2010 were reviewed. Of the 102 patients, 62 were treated with high-dose regimens including cisplatin, 5-fluorouracil, methotrexate, leucovorin or docetaxel, cisplatin, and 5-fluorouracil. The remaining 40 were treated with low-dose regimens including carboplatin and uracil-tegafur, weekly docetaxel, or S-1. Radiotherapy was delivered 5 days a week using a single daily fraction of 1.8–2.0 Gray (Gy), to a total dose of 64.8–70.2 Gy. Overall survival (OS), disease-specific survival (DSS), and DSS with larynx preservation were estimated using Kaplan–Meier methods. The log-rank test and Cox proportional hazards regression were used to identify significant prognostic factors for OS, DSS, and DSS with larynx preservation.
Results
The 5-year OS and DSS for all patients treated with CCRT were 51.3 and 64.3 %, respectively. The 5-year DSS with larynx preservation was 55.5 %. On multivariate analysis, the content of chemotherapy was a significant predictor of OS and DSS for patients undergoing CCRT; N stage was a significant prognostic factor for DSS and larynx preservation.
Conclusion
The treatment method including the indication for CCRT may be determined by the contents of the chemotherapy and the N stages of SCC of the hypopharynx.
Similar content being viewed by others
References
Prades JM, Lallemant B, Garrel R, Reyt E, Righini C, Schmitt T, Remini N, Saban-Roche L, Timoshenko AP, Trombert B, Guerrier B (2010) Randomized phase III trial comparing induction chemotherapy followed by radiotherapy to concomitant chemoradiotherapy for laryngeal preservation in T3M0 pyriform sinus carcinoma. Acta Otolaryngol 130:150–155
Hussey DH, Latourette HB, Panje WR (1991) Head and neck cancer: an analysis of the incidence, patterns of treatment, and survival at the University of Iowa. Ann Otol Rhinol Laryngol Suppl 152:2–16
Lefebvre JL, Chevalier D, Luboinski B, Kirkpatrick A, Collette L, Sahmoud T (1996) Larynx preservation in pyriform sinus cancer: preliminary results of a European Organization for Research and Treatment of Cancer phase III trial. EORTC Head and Neck Cancer Cooperative Group. J Natl Cancer Inst 88:890–899
Pointreau Y, Garaud P, Chapet S, Sire C, Tuchais C, Tortochaux J, Faivre S, Guerrif S, Alfonsi M, Calais G (2009) Randomized trial of induction chemotherapy with cisplatin and 5-fluorouracil with or without docetaxel for larynx preservation. J Natl Cancer Inst 101:498–506
Posner MR, Norris CM, Wirth LJ, Shin DM, Cullen KJ, Winquist EW, Blajman CR, Mickiewicz EA, Frenette GP, Plinar LF, Cohen RB, Steinbrenner LM, Freue JM, Gorbunova VA, Tjulandin SA, Raez LE, Adkins DR, Tishler RB, Roessner MR, Haddad RI (2009) Sequential therapy for the locally advanced larynx and hypopharynx cancer subgroup in TAX 324: survival, surgery, and organ preservation. Ann Oncol 20:921–927
Tsukuda M, Ishitoya J, Matsuda H, Horiuchi C, Taguchi T, Takahashi M, Nishimura G, Kawakami M, Watanabe M, Niho T, Kawano T, Ikeda Y, Sakuma Y, Shiono O, Komatsu M (2010) Randomized controlled phase II comparison study of concurrent chemoradiotherapy with docetaxel, cisplatin, and 5-fluorouracil versus CCRT with cisplatin, 5-fluorouracil, methotrexate and leucovorin in patients with locally advanced squamous cell carcinoma of the head and neck. Cancer Chemother Pharmacol 66:729–736
Taguchi T, Ikeda Y, Mikami Y, Kawai S, Arai Y, Mochimatsu I, Tsukuda M (2003) Combined radiotherapy and chemotherapy with carboplatin and UFT for head and neck squamous cell carcinoma. Anticancer Res 23:713–717
Tsukuda M, Ishitoya J, Mikami Y, Matsuda H, Horiuchi C, Taguchi T, Satake K, Kawano T, Takahashi M, Nishimura G, Kawakami M, Sakuma Y, Watanabe M, Shiono O, Komatsu M, Yamashita Y (2009) Analysis of feasibility and toxicity of concurrent chemoradiotherapy with S-1 for locally advanced squamous cell carcinoma of the head and neck in elderly cases and/or cases with comorbidity. Cancer Chemother Pharmacol 64:945–952
Kodaira T, Fuwa N, Furutani K, Tachibana H, Yamazaki T (2005) Phase I trial of weekly docetaxel and concurrent radiotherapy for head and neck cancer in elderly patients or patients with complications. Jpn J Clin Oncol 35:173–176
Cox JD, Stetz J, Pajak TF (1995) Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys 31:1341–1346
Machtay M, Moughan J, Trotti A, Garden AS, Weber RS, Cooper JS, Forastiere A, Ang KK (2008) Factors associated with severe late toxicity after concurrent chemoradiation for locally advanced head and neck cancer: an RTOG analysis. J Clin Oncol 26:3582–3589
Suntharalingam M, Haas ML, Van Echo DA, Haddad R, Jacobs MC, Levy S, Gray WC, Ord RA, Conley BA (2001) Predictors of response and survival after concurrent chemotherapy and radiation for locally advanced squamous cell carcinomas of the head and neck. Cancer 91:548–554
Douple EB, Richmond RC, O’Hara JA, Coughlin CT (1985) Carboplatin as a potentiator of radiation therapy. Cancer Treat Rev 12(Suppl A):111–124
Colevas AD, Posner MR (1998) Docetaxel in head and neck cancer: a review. Am J Clin Oncol 21:482–486
Fu KK, Phillips TL (1991) Biologic rationale of combined radiotherapy and chemotherapy. Hematol Oncol Clin North Am 5:737–751
Smalley SR, Kimler BF, Evans RG (1991) 5-Fluorouracil modulation of radiosensitivity in cultured human carcinoma cells. Int J Radiat Oncol Biol Phys 20:207–211
Katori H, Tsukuda M, Taguchi T (2007) Concurrent chemoradiotherapy with carboplatin and uracil-f tegafur (UFT) for patients with poor performance status with locally advanced squamous cell carcinoma of the head and neck (SCCHN). Acta Otolaryngol 127:1099–1104
Fujii M, Tsukuda M, Satake B, Kubota A, Kida A, Kohno N, Okami K, Inuyama Y (2004) Phase I/II trial of weekly docetaxel and concomitant radiotherapy for squamous cell carcinoma of the head and neck. Int J Clin Oncol 9:107–112
Lodder WL, Pameijer FA, Rasch CR, van den Brekel MW, Balm AJ (2012) Prognostic significance of radiologically determined neck node volume in head and neck cancer: a systematic review. Oral Oncol 48:298–302
Tsou YA, Hua JH, Lin MH, Tsai MH (2006) Analysis of prognostic factors of chemoradiation therapy for advanced hypopharyngeal cancer—does tumor volume correlate with central necrosis and tumor pathology? ORL J Otorhinolaryngol Relat Spec 68:206–212
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Taguchi, T., Nishimura, G., Takahashi, M. et al. Treatment results and prognostic factors for advanced squamous cell carcinoma of the hypopharynx treated with concurrent chemoradiotherapy. Cancer Chemother Pharmacol 73, 1147–1154 (2014). https://doi.org/10.1007/s00280-014-2448-2
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00280-014-2448-2